10-Q · May 8, 2026
Artivion reported Q1 2026 results with revenues of $116.3 million, reflecting an 18% year-over-year growth, but EPS came in lower at $0.08 against the estimate of $0.11. The company revised its full-year revenue…
Earnings analysis · 10-Q
AORT earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
Artivion delivered a strong Q2 2026, with revenue of $125.757 million, up 8.4% sequentially and 11.3% year over year, while diluted EPS increased to $0.13 from $0.03 in both comparison periods. Results exceeded…
Read full summary
Artivion delivered a strong Q2 2026, with revenue of $125.757 million, up 8.4% sequentially and 11.3% year over year, while diluted EPS increased to $0.13 from $0.03 in both comparison periods. Results exceeded consensus for both revenue and EPS, and the Endospan acquisition expanded the company’s aortic portfolio through the NEXUS products. The principal risks are geopolitical and supply-chain exposure at the Israel-based NEXUS facility, a potential Italian government repayment of approximately $2.3 million, and uncertainty surrounding recent U.S. tax and healthcare legislation.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.13
What stood out
-
Revenue Accelerated
Q2 revenue was $125.757 million, up from $116 million in Q1 2026 and $113 million in Q2 2025, representing approximately 8.4% sequential growth and 11.3% year-over-year growth.
-
EPS Improved and Beat Estimates
Diluted EPS was $0.13 versus $0.03 in both Q1 2026 and Q2 2025. EPS also exceeded the $0.10 consensus estimate by $0.03.
-
Revenue Beat Estimates
Revenue exceeded the $120.19 million consensus estimate by $5.567 million, or approximately 4.6%.
-
Endospan Adds Aortic Portfolio
The Endospan acquisition closed on May 18, 2026, adding the NEXUS product family and a manufacturing facility in Herzliya, Israel.
-
Controls Remain Effective
Management reported no material change in market-risk disclosures as of June 30, 2026, and concluded that disclosure controls were effective at a reasonable assurance level.
What to watch
-
NEXUS Israel Supply Exposure
The acquired NEXUS family of products is solely manufactured in Herzliya, Israel. The filing states that no material NEXUS supply disruption has occurred from the war in Iran, but escalation could cause shortages, freight delays, higher costs, or other supply-chain disruptions.
-
Italian Payback Liability
The Italian government is assessing medical-device spending amounts for 2019-2024, and Artivion estimates potential repayment exposure for the entire 2019-2025 period at approximately $2.3 million.
-
U.S. Tax and Healthcare Changes
The filing highlights that the July 4, 2025 One Big Beautiful Bill Act changes U.S. tax and healthcare laws, including corporate tax and business-deduction provisions; interpretive guidance could adversely affect results, although the company has not yet quantified the impact.
Management's outlook
The provided 10-Q extract does not include a quantitative outlook or explicit guidance update. The prior Q1 2026 outlook was revenue of $480 million-$496 million, but the current filing text does not state whether that outlook was maintained, raised, or lowered.
Earlier filings 4
10-K · February 18, 2026
Artivion’s 2025 results show top-line recovery and margin stability: quarterly revenue climbed to $116M in 2025Q4 and full-year revenue totaled roughly $441M (sum of 2025 quarters). Gross margins remained around the…
10-Q · November 7, 2025
Artivion reported Q3 2025 revenue of $113,388,000 and gross margin of $74,395,000 (≈65.6%), driving operating income of $12,536,000 and GAAP net income of $6,502,000 (diluted EPS $0.13). The quarter shows meaningful…
10-Q · August 8, 2025
Artivion reported Q2 revenue of $112,972,000, up $14,953,000 versus Q2 2024 ($98,019,000), with gross margin of 64.7% and operating income of $8,384,000 (7.4% operating margin). GAAP diluted EPS was $0.03 and net income…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.